Antimicrobial Agents and Chemotherapy
December 2000, p. 3288-3297, Vol. 44, No. 12
Ute Dreses-Werringloer1, Ingrid Padubrin1,
Barbara Jurgens-Saathoff1, Alan P. Hudson2,
H. Zeidler1, and L. Kohler1,
Department of Rheumatology, Hannover Medical School, Hannover, Germany1,
and Department of Immunology and Microbiology, Wayne State University
School of Medicine, Detroit, Michigan 492012
ABSTRACT
An in vitro cell culture model was used to investigate the long-term
effect of ciprofloxacin and ofloxacin on infection with Chlamydia
trachomatis. Standard in vitro susceptibility testing clearly indicated
successful suppression of chlamydial growth. To mimic better in
vivo infection conditions, extended treatment with the drugs was
started after infection in vitro had been well established. Incubation
of such established chlamydial cultures with ciprofloxacin and ofloxacin
not only failed to eradicate the organism from host cells, but rather
induced a state of chlamydial persistence. This state was characterized
by the presence of nonculturable, but fully viable, bacteria and
the development of aberrant inclusions.
In addition chlamydia exhibited altered steady-state levels of
key chlamydial antigens, with significantly reduced major outer
membrane protein and near constant hsp60 levels. Resumption of overt
chlamydial growth occurred after withdrawal of ciprofloxacin, confirming
the viability of persisting chlamydia. In vitro ciprofloxacin results
are consistent with clinical data, thereby providing an explanation
for treatment failures of ciprofloxacin. Parallel in vitro studies
with ofloxacin suggest a better correlation between clinical and
laboratory-defined efficacy, although the clinical studies on which
this assessment is based did not include monitoring of chlamydial
persistence.
The data presented here clearly demonstrate that under at least
some circumstances, standard determination of MICs and minimal bactericidal
concentrations for C. trachomatis allows no more than a simple definition
of whether an antibiotic has some anti chlamydial activity; however,
such testing is not always sufficient to verify that the antibiotic
will eliminate the organism in vivo.
|
|
.........................................................................................
We're sorry you are having to learn about prostatitis, but we're glad you came here, because we think we can help. Please be advised that the Prostatitis Foundation does
not warrant, support, sponsor, endorse, recommend or accept responsibility for any health care provider or any treatment or protocol performed by any heath care provider.
© The
Prostatitis Foundation
.........................................................................................
|